This site is intended only for healthcare professionals resident in Egypt

Search

Menu

Close

Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information

Menu

Close

Clinical Information​Stroke Prevention in Atrial Fibrillation​Morbidity and Mortality​Efficacy​Aristophanes​Safety​Real-world Data​Guideline recommendations​Persistence and Adherence​Dosing​Summary​Venous Thromboembolism TreatmentEfficacySafety​Real-world Data​Guideline recommendationsDosing​Venous Thromboembolism PreventionEfficacy​Safety​Dosing​Eliquis Important Safety InformationEliquis Abbreviated Prescribing Information (2.5 mg)​Eliquis Abbreviated Prescribing Information (5 mg) Support & Services​ Support & Services​ Self-detail presentations​ Webinars​ Videos​

Overview​

Eliquis® can benefit a broad range of NVAF patients1​

NVAF patients treated with Eliquis® had consistently fewer strokes and bleeds across a broad range of subgroup populations and risk profiles vs. warfarin2​

*Patients with severe renal insufficiency (CrCl <25 mL/min) were excluded from ARISTOTLE and Eliquis® is not recommended for patients with CrCl <15 mL/min, or in patients undergoing dialysis.1​
CrCl: creatinine clearance; NVAF: non-valvular atrial fibrillation; TIA: transient ischaemic attack​; VTE: venous thromboembolism.
References: 1. Eliquis 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022. 2.Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. 3. Garcia DA, Wallentin L, Lopes RD, et al. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2013;166(3):549-558. 4. Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11(6):503-511. 5. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J.2012;33(22):2821-2830. 6. Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial​ fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864-1872.​

Stroke

Eliquis® demonstrated consistent benefits across NVAF patients with a wide range of stroke risks3​

Adapted from Lopes RD.et al. Lancet. 2012.

Adapted from Lopes RD.et al. Lancet. 2012.

*As assessed by CHADS2, CHA2DS2-VASc scores.3 Stroke or systemic embolism was the primary efficacy endpoint and major bleeding was the primary safety endpoint of the ARISTOTLE trial.3​
†P for interaction.3
CHA2DS2: Congestive Heart Failure, Hypertension, Age ≥75, Diabetes, Stroke (doubled); CHA2DS2-VASc: Congestive Heart Failure, Hypertension, Age ≥75 (doubled), Diabetes, Stroke(doubled), Vascular Disease, Age 65-74, Sex Category, Female; CI: confidence​ interval; HR: hazard ratio; NVAF: non-valvular atrial fibrillation.​

References: 1. Eliquis 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022.
Revision Date: February 2022. 2. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban
versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
3. Lopes RD, Al-Khatib SM, WallentinL, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial. Lancet. 2012;380(9855):1749-1758.

Prior Stroke/TIA​

Eliquis® demonstrated consistent benefits across NVAF patients with or without prior stroke3*​

Adapted from Granger CB, et al. N Engl J Med. 2011.

 *Patients with prior stroke or TIA: A post-hoc subgroup analysis of the ARISTOTLE trial.3
Patients with a previous ICH or any stroke within 7 days before random assignment were excluded.3 Stroke/systemic embolism was the primary efficacy endpoint, and major bleeding was the primary safety endpoint of the ARISTOTLE trial.​2

CI: confidence interval; HR: hazard ratio; ICH: intracranial haemorrhage; NVAF: nonvalvular atrial fibrillation; RRR: relative risk reduction; TIA: transient ischaemic attack.​

References: 1. Eliquis 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022. 2.Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. 3. Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11(6):503-511.​

Prior Warfarin Experience​

Eliquis® demonstrated consistent benefits regardless of NVAF patients’ experience with VKA treatment3*​ †The comparison of the primary safety outcome of bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria is in the hierarchical sequence preserving a type I error.​

References: 1. Eliquis 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022.  2. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. 3. Garcia DA, Wallentin L, Lopes RD, et al. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2013;166(3):549-558.
​

Renal Function​

Eliquis® demonstrated consistent benefits across NVAF patients with mild-to-moderate renal impairment3*​
*Pre-specified Subgroups: Age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or more.3 Stroke or systemic embolism was the primary efficacy endpoint and major bleeding was the primary safety endpoint of the ARISTOTLE trial.2 Patients with a CrCl clearance of <25 mL/min were excluded from the trial.2 A dose reduction to 2.5 mg of Eliquis® is recommended for patients with CrCl 15-29 mL/min †The comparison of the primary safety outcome of bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria is in the hierarchical sequence preserving a type I error​ and Eliquis® is not recommended for patients with CrCl <15 mL/min.1​

CrCl: creatinine clearance; CI: confidence interval; HR: hazard ratio; NVAF: non-valvular atrial fibrillation; RRR: relative risk reduction; TIA: transient ischaemic attack.​References: 1. Eliquis 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022. 2. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. 3. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821-2830.​

Age​

Eliquis® demonstrated consistent benefits across non-valvular AF patients regardless of their age subgroup2​ *Interaction p-values are based on continuous age2

AF, atrial fibrillation; CrCl: creatinine clearance; CI: confidence interval; HR: hazard ratio; NVAF: non-valvular atrial fibrillation; RRR: relative risk reduction; TIA: transient ischaemic attack.​

Reference: 1. Eliquis 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022. 2. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.​

















VTE: venous thromboembolism.
References: 1. Eliquis 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022. 2. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.

Explore more​VTE prevention Efficacy Learn more Loading
Click here for Eliquis® 2.5mg Prescribing Information

Click here for Eliquis® 5mg Prescribing Information
HF0098OA451/122022​
Invalidation Date : 21/08/2024​
Quick Links
SPAF Guideline recommendations
 Learn moreLoading
VTE treatment Guideline recommendations
 Learn more Loading
PP-ELI-EGY-0467

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 

 

Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.

 

PP-UNP-EGY-0064
You are leaving the Pfizer for Professionals website
​
You are being directed to a third-party website:

This link is provided for your convenience. Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.
 
PP-UNP-EGY-0064
For Healthcare Professionals only

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
 

If you select ‘No’, you will be redirected to Pfizer.com, the global Pfizer website.
 

I confirm that I am a healthcare professional resident in Egypt.
 

PP-UNP-EGY-0064

Yes No